
Patients with zzso mantle cell zzso zzso still represent a demanding challenge for the zzso The dismal prognosis and the absence of generally accepted therapeutic standards hamper the clinical management of such zzso Moreover, the availability of many targeted approaches, in a field so far missing efficient salvage regimens, challenges current therapeutic zzso in these zzso 

zzso targeted drugs provide unprecedented response rates in relapsed and even zzso zzso Many phase II studies demonstrated impressive zzso activity of compounds such as zzso zzso and zzso whereas ongoing phase III trials currently assess the zzso zzso benefit and the impact on survival, both alone and in combination with chemotherapy or zzso zzso Recently, the zzso zzso zzso inhibitor zzso targeting the zzso zzso zzso showed impressive response rates and will be soon available in phase III zzso 

In the present review we focus on the major therapeutic discoveries of the last few years to offer a practical zzso to select the appropriate treatment in patients with relapsed zzso 

